Hedge Funds Carl Icahn

  • More than $18 billion in pharmaceutical drugs are scheduled to go off-patent this year, and consequently medication makers are getting lots of attention from Wall Street. One company expected to benefit from patent expiration is generic drug manufacturer Mylan Labs. CNBC's Mike Huckman caught up with CEO Robert Coury at the JPMorgan Healthcare Conference in San Francisco.

  • NAHB

    Last week the Secretary of the Treasury, Hank Paulson, was asked if the residential real estate market had bottomed.  He refused to answer the question.  But as we approach the New Year, that is arguably the biggest question in real estate.  The spring season is right around the corner, traditionally the busiest for buying and selling, and many believe it will tell the true story of the state of the market.

  • But billionaire investor Carl Icahn, who had made his own Reckson bid, hinted he would not abandon his fight for some office buildings included the deal.

  • Reckson Associates Realty's shareholders approved a merger with SL Green Realty after market close Thursday.

  • Real estate investment trust Reckson Associates Realty Tuesday rejected a takeover bid from billionaire Carl Icahn, favoring a competing bid from SL Green Realty.

  • Real estate investment trust Reckson Associates Realty  Tuesday rejected a takeover bid from billionaire Carl Icahn, favoring a competing bid from SL Green Realty.

  • Shares of South Korean tobacco firm KT&G skidded on news U.S. investor Carl Icahn has sold his stake in the company at a discount.

  • Billionaire financier Carl Icahn charged ahead on Monday with an offer for New York office landlord Reckson Associates Realty for $49 a share after his two partners withdrew from the bidding.